Uric Acid and Two Answers

Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect was 72.7% explained by weight loss; the other found it was independent of weight loss entirely.^[1][2] They also disagree about the size of the effect by a factor of five, and a reader who met either one alone would come away confident about something the other contradicts.

Why uric acid matters here

Uric acid is the substance that crystallizes in joints to cause gout, and gout is disproportionately common in people carrying excess weight. Treatment is managed to a target: bring serum urate below 6.0 mg/dL and crystals dissolve rather than form.

That threshold is what makes the size of any reduction the whole question. A fall of a full milligram per deciliter can carry someone across the line. A fall of two-tenths cannot.

The randomized answer

A post hoc analysis of SURMOUNT-1 tracked serum urate in 2,539 adults with obesity or overweight across 72 weeks of tirzepatide or placebo.^[1]

All active doses beat placebo at P<.001, and the reduction happened regardless of where someone started — it did not matter which quartile of baseline urate they were in (P = .610) or what their BMI was (P = .362). Mediation analysis then attributed 72.7% of the urate reduction to the weight loss itself.

The real-world answer

URISEMA looked retrospectively at 236 people with type 2 diabetes prescribed oral semaglutide, with a median age of 64 and a BMI of 33.8.^[2]

• Overall urate fell 0.1 mg/dL at six months — which was not statistically significant (P = 0.52) — and 0.2 mg/dL at twelve months (P = 0.01).
• In people who started above 6 mg/dL, reductions were larger: 0.6 and 0.8 mg/dL.
• The changes were independent of weight loss, of improved blood sugar control, and of prior GLP-1 or SGLT2 inhibitor use.

One study says the weight loss did nearly three-quarters of the work. The other says the weight loss did none of it.

How both can be reported honestly

They are not the same experiment. The differences are large enough to explain a lot without anyone being wrong.

The last two rows do most of the work. If weight loss drives urate down, a trial producing 20% weight loss will show a large effect largely explained by weight — and a real-world cohort losing far less will show a small effect that weight cannot explain, because there was not enough weight change to explain it with. Two-thirds of the URISEMA cohort were already under the treatment target before starting.

That reading is consistent with both and is not established by either. It is what a careful reader should hold: probably weight-driven at large weight losses, possibly something else at small ones, with no study yet designed to separate them.

What neither study did

So the supportable claim is narrow: these drugs lower serum uric acid, by an amount that depends heavily on how much weight comes off. Whether that translates into fewer gout attacks is untested, and the authors of the randomized analysis say as much — that their findings warrant further investigation into a possible role in treating gout.

One further caution on URISEMA’s predictors. The two factors it identified — starting above 7 mg/dL, and switching from a DPP-4 inhibitor — carry odds ratios of 4.54 and 6.53 with intervals running to 19.25 and 27.32. In 236 retrospective patients, intervals that wide establish a direction and very little else.